The GenieFluor Violet 450 Anti-Human CD197 (CCR7) Antibody (G043H7) offered by AssayGenie is a highly specific and sensitive tool for researchers studying the immune system. This antibody targets CD197, also known as CCR7, a cell surface receptor crucial for the movement and positioning of immune cells in the body. With its violet 450 fluorophore, this antibody allows for precise detection and visualization of CD197/CCR7 in human samples using flow cytometry and immunofluorescence techniques. The high affinity and specificity of this antibody ensure accurate results in various experimental settings, making it an essential tool for immunology and cell biology research.
CD197/CCR7 is particularly important in the context of immune cell migration, lymph node homing, and immune responses to pathogens. By targeting this key receptor, researchers can gain valuable insights into the mechanisms underlying immune cell trafficking and the development of targeted therapies for immune-related disorders.For scientists interested in investigating the role of CD197/CCR7 in immune function, inflammation, cancer metastasis, or vaccine response, the GenieFluor Violet 450 Anti-Human CD197 (CCR7) Antibody (G043H7) is a reliable and effective choice for their research needs.
Each lot of this antibody is quality control tested by flow cytometric analysis. The amount of the reagent is suggested to be used 5 µL of antibody per test (million cells in 100 µL staining volume or per 100 µL of whole blood). Please check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use.
Spectrum:
Swissprot:
P32248
Gene ID:
1236
Storage Buffer:
Phosphate buffered solution, pH 7.2, containing 0.09% stabilizer and 1% protein protectant.
Stability & Storage:
Keep as concentrated solution. Store at 2~8°C and protected from prolonged exposure to light. Do not freeze. Centrifuge before opening to ensure complete recovery of vial contents. This product is guaranteed up to one year from purchase.
Background:
CCR7, also known as CD197, is a chemokine receptor that binds CCL19 and CCL21. CCR7 and its ligands link innate and adaptive immunity by affecting interactions between T cells and dendritic cells and their downstream effect. Naïve T cells enter the lymph node through high endothelial venules, which express CCL21. Dendritic cells and macrophages enter the lymph node through afferent lymphatics. The encounter of T cells and dendritic cells in the T cell zone is CCR7-dependent. In addition, during immunological surveillance, B cells recirculate between B-cell-rich compartments (follicles or B cell zones) in secondary lymphoid organs, surveying for antigen. After antigen binding, B cells move to the boundary of B and T zones to interact with T-helper cells; this B cell migration is directed by CCR7 and its ligands. CCR7-positive cancer cell expression has been associated with lymph node metastasis.